TXMD
TherapeuticsMD, Inc.
$1.97
+0.00 (+0.00%)
At close · Jul 8
View the 10-Q filed May 12, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three months ended March 31, 2026)
“For the three months ended March 31, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$22.80M
Shares
11,574,362
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.97
Open$1.98
Day$1.94–2.03
52W$0.99–2.95
Avg vol 30d59K
Short int46K · 0.4% float · 1.0d
Short vol26%
Last earningsMay 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+5%
above
Price vs 50-day avg
−4%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
50%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
−6%
trailing
YTD return
+21%
this year
Relative strength
−14%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.40% of float · ▼ -10.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
50 holders — near 3-yr high, broad support
Squeeze score
21
low risk · 0–100
Fundamentals
Revenue growth
+35%
Y/Y
Gross margin
74%
contracting
EPS growth
+74%
Y/Y
Free cash flow
$-142.7M
Valuation
P/E 98.5
rich
Balance sheet
$183.2M
net debt
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
7.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+5%
Bullish
Price vs 50-day avg
−4%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
50%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.40% of float · ▼ -10.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
50 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 50%
52-wk high $3
vs 200-day avg +5%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TXMD
this stock
TherapeuticsMD, Inc.
|
$22.80M | +20.9% | +35.3% | 98.5 | 0.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.49B | +7.4% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$51.02B | +4.9% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.94B | -3.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TXMD | -10.9% | +4.8% | -6.2% | -10.9% | +20.9% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -10.7% | +4.0% | -13.6% | -10.7% | +11.6% |